ストックスクリーナーアプリを入手
10.17
4.41%
0.43
前日終値:
$9.74
開ける：
$9.75
24時間の取引高:
281.55K
Relative Volume:
1.03
時価総額：
$813.48M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-1.26%
1か月 パフォーマンス:
-13.00%
6か月 パフォーマンス:
+0.89%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$9.60
$10.31
1週間の範囲:
$9.50
$10.59
52週間の値動き範囲:
$8.70
$14.87
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Company Profile
名前
Bridgebio Oncology Therapeutics Inc
セクター
電話
857 702 0377
住所
256 E. GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Compare BBOT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBOT
Bridgebio Oncology Therapeutics Inc
|
10.17 | 779.09M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Oncology Therapeutics Inc Stock (BBOT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-11 | 開始されました | Stifel | Buy |
| 2026-01-09 | 開始されました | Raymond James | Outperform |
| 2025-12-05 | 開始されました | Morgan Stanley | Overweight |
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-09-15 | 開始されました | H.C. Wainwright | Buy |
| 2025-08-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Bridgebio Oncology Therapeutics Inc (BBOT) 最新ニュース
BBOT Technical Analysis & Stock Price Forecast - Intellectia AI
HLXB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
BridgeBio Oncology Therapeutics Inc expected to post a loss of 52 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BBOT Should I Buy - Intellectia AI
BBOT: Novel RAS-targeted therapies show strong efficacy and safety, with major data readouts expected soon - TradingView
BBOT: Major data from three RAS-focused assets expected in H2, highlighting strong efficacy and safety - TradingView
HLXB SEC FilingsHelix Acqsn II 10-K, 10-Q, 8-K Forms - Stock Titan
BridgeBio Oncology (BBOT) Stock Analysis Report | Financials & Insights - Benzinga Japan
BBOT to Participate in Upcoming Investor Healthcare Conferences - Bitget
Stifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy Recommendation - Nasdaq
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Nicolaus Initiates Coverage on BridgeBio Oncology Therapeutics With Buy Rating, $23 Price Target - marketscreener.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating - Investing.com
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating By Investing.com - Investing.com India
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
A Look At BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Momentum - Yahoo Finance
Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results - Finviz
BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis - MarketBeat
Top BridgeBio Oncology Therapeutics (BBOT) Competitors 2026 - MarketBeat
BridgeBio Oncology Therapeutics (BBOT) Stock Trends and Sentiment 2026 - MarketBeat
BBOT: Robust efficacy and safety data position these assets as leaders in KRAS-targeted cancer therapy - TradingView — Track All Markets
Raymond James Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Outperform Recommendation - Nasdaq
BridgeBio Oncology stock initiated with Outperform rating at Raymond James By Investing.com - Investing.com Nigeria
Raymond James Initiates BridgeBio Oncology Therapeutics at Outperform With $24 Price Target - marketscreener.com
BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com
BridgeBio Oncology stock price target raised to $32 from $25 at Leerink - Investing.com Canada
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley By Investing.com - Investing.com Nigeria
Oppenheimer reiterates Outperform rating on BridgeBio Oncology stock By Investing.com - Investing.com Canada
BridgeBio Oncology stock maintains Overweight rating at Morgan Stanley - Investing.com
BBOT: Promising efficacy and safety for three RAS-pathway inhibitors, with key data expected in 2026 - TradingView — Track All Markets
BridgeBio Oncology reports positive data from RAS-pathway cancer trials - Investing.com
BridgeBio Oncology reports positive data from RAS-pathway cancer trials By Investing.com - Investing.com Nigeria
BridgeBio Oncology Therapeutics, Inc. Announces New Clinical Data for RAS and PI3Kα Programs - TradingView — Track All Markets
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs - The Manila Times
BridgeBio Oncology Therapeutics, Inc.Common Stock (NQ: BBOT - FinancialContent
BridgeBio Oncology Therapeutics, Inc.(NasdaqGM: BBOT) added to S&P Global BMI Index - marketscreener.com
BridgeBio Oncology Therapeutics Earnings Notes - Trefis
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Assessing BridgeBio Oncology Therapeutics (BBOT) Valuation After Recent Share Price Pullback - Yahoo Finance
Wedbush Reiterates BridgeBio Oncology Therapeutics (BBOT) Outperform Recommendation - MSN
BridgeBio Oncology Therapeutics (BBOT) updates CEO option grant terms - Stock Titan
BridgeBio Oncology Therapeutics: Promising KRAS Drug DeveloperIn My View, At Least - Seeking Alpha
Bridgebio Oncology Therapeutics Inc (BBOT) 財務データ
Bridgebio Oncology Therapeutics Inc (BBOT) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):